CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV – Press Release – Digital Journal

• Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
• Submission of CVnCoV pre-clinical data package marks start of the rolling process

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 12, 2021 / CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA)…

Click here to view the original article.